Table 1.

Characteristics of the included studies comparing trifocal and the hybrid multifocal-extended depth of focus IOLs (n = 13).

Author, year	Study design	Location	Follow-up (months)	IOL types	Patients (n)	Eyes (n)	Age (years)	Gender (male/female)	Quality Score
Hamid and Sokwala, 201611	NRCS	UK	6	FineVision	50	100	58.2 ± 9.4	17/33	8
				AT LISA tri 839MP	50	100	56.9 ± 7.0	17/33
				Symfony	50	100	57.8 ± 6.0	17/33
Monaco, 201722	RCT	Italy	4	PanOptix	20	40	66.0 ± 5.5	11/9	4a
				Symfony	20	40	67.0 ± 8.5	9/11
Ruiz-Mesa, 201724	NRCS	Spain	12	FineVision	20	40	54.5 ± 7.2	9/11	8
				Symfony	20	40	59.5 ± 8.9	8/12
Cochener, 20187	RCT	France	6	PanOptix	20	40	62.5 ± 4.6	NR	2a
				FineVision	20	40	62.5 ± 4.6	NR
				Symfony	20	40	69.2 ± 8.4	NR
Escandón-García, 201819	NRCS	Portugal	1–3	PanOptix	7	14	62.3 ± 9.0	1/6	7
				FineVision	23	46	62.6 ± 8.0	7/16
				Symfony	15	30	63.5 ± 9.4	2/13
Mencucci, 201821	NRCS	Italy	3	PanOptix	20	40	70.1 ± 4.8	NR	8
				AT LISA tri 839MP	20	40	71.6 ± 4.4	NR
				Symfony	20	40	68.9 ± 4.8	NR
Ruiz-Mesa, 201825	NRCS	Spain	8–28	PanOptix	20	40	63.8 ± 8.1	14/6	8
				Symfony	14	28	63.1 ± 10.0	5/9
Böhm, 201913	NRCS	Germany	3	PanOptix	27	54	63.4 ± 8.9	13/14	7
				AT LISA tri 839MP	27	54	63.5 ± 7.9	10/17
				Symfony	26	52	69.2 ± 8.2	18/8
de Medeiros, 20194	NRCS	Brazil	6–12	PanOptix	13	26	NR	(12/14)b	8
				Symfony	13	26	NR
Rodov, 201923	NRCS	Israel	1	FineVision	50	100	67.0 ± 6.7	14/36	6
				Symfony	50	100	67.2 ± 9.8	26/24
Singh, 201928	NRCS	India	6	FineVision	20	40	66.1 ± 5.1	8/12	8
				Symfony	20	40	69.1 ± 6.1	9/11
Gil, 202020	RCT	Spain	6	AT LISA tri 839MP	10	19	68.7 ± 10.3	2/8	4a
				Symfony	10	20	68.2 ± 6.2	3/8
Webers, 202027	RCT	Netherlands	3	AT LISA tri 839MP	13	26	70.4 ± 6.1	6/7	5a
				Symfony	14	28	67.6 ± 12.2	4/10

IOL, intraocular lens; RCT, randomized controlled trial; NRCS, non-randomized controlled study; NR, not reported.

^aRCTs assessed with the Jaded Scale.

^bThe ratio for both groups, no separate data provided.